-
-
-
-
-
-
-
Fresh Tracks Therapeutics (FRTX) Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02
-
-
-
-
-
-
-
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
-
-
-
-
-
-
-
Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting
-
-
-
-
-
-
-
Brickell Biotech (BBI) Prices 26.3M Share Offering at $0.38/sh
-
-
-
-
-
-
-
Brickell Biotech to Participate at Upcoming September Conferences
-
-
-
-
-
-
-
Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter’s Option to Purchase Additional Shares
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

